Kidney Stones

Both the Dornier Hoover Flexible and Navigable Suction Ureteral Access Sheath and the Dornier Axis II Slim single-use ureteroscope are FDA-cleared.

The Focalist device obtained FDA clearance in the US in July 2025.

Two-year outcomes from the ASPIRE trial continued to show that the SURE procedure led to significantly reduced health care consumption events compared with ureteroscopy.

We recap notable headlines from last month in the benign urology space.

The findings suggest that urolithiasis continues to pose a significant healthcare burden worldwide.

New findings from the PKIDS trial raise questions about the preference for ureteroscopy in clinical practice.

"What we showed was that there's no difference in the pressures whether you use CVAC or standard ureteroscopy," says Roger Sur, MD.

The first patient has been dosed in the phase 1/2 redePHine trial, evaluating the safety and preliminary efficacy of ABO-101 for PH1.

The code, 0991T, will become effective on January 1, 2026.

Amy E. Krambeck, MD, discusses how to define success and how to determine the optimal timing for adding on a new partner.

David Stanley, MD, FACS, discusses current trends and unmet needs in the treatment of patients with kidney stones.

Margaret A. Knoedler, MD, discusses the advantages of using the MONARCH platform for mini-PCNL.

Khurshid R. Ghani, MBChB, MS, FRCS, discusses how results from the SOUL trial may shape clinical decision-making regarding stent placement.

The study compared patient experiences with silicone vs polyurethane ureteral stents.

“It is possible to conserve fluid when we're trying to do these procedures without compromising patient care," says Roshan M. Patel, MD.

"We...observed an exceedingly high degree of safety across the board, with very few complications,” says Jared S. Winoker, MD.

Jared S. Winoker, MD, addresses the wide range of stone burdens treated by the CVAC system for the study.

The risk of stricture formation was 4.6% in the TFL cohort vs 2.4% in the holmium laser cohort.

"There was a significant increase in overall fatigue after performing flexible ureteroscopy," says Sarah Razavi, MD.

Professor Andreas Skolarikos shares his experience with the LithoVue Elite System.

Joshua M. Heiman, MD, details key findings from the POuND OUT study.

John Michael DiBianco, MD, discusses findings from the BLUES trial.

Patient-reported pain scores were significantly improved with stent omission.

“We do not feel that our results undermine the importance of fluid intake for stone prevention," says Alana C. Desai, MD.

DiBianco discusses findings from the Better Lithotripsy and Ureteroscopy Evaluation of Stenting trial.